Open in Screener

STOK

Stoke Therapeutics Inc

Mar 17 • 04:00PM ET

32.87

-1.09 -3.21 %

Healthcare • Biotechnology • USA • NASD

Peers: SRPT PTCT FOLD RARE NTLA CRSP EDIT ARWR VRTX ALNY

| Held by: VTI XBI IWM VXF IWO IBB SCHA VTWO DFAS FDM

Index	RUT	P/E	-	EPS (ttm)	-0.15	Insider Own	22.07%	Shs Outstand	58.92M	Perf Week	-14.29%
Market Cap	1.88B	Forward P/E	-	EPS next Y	-3.30	Insider Trans	-2.12%	Shs Float	44.51M	Perf Month	3.01%
Enterprise Value	1.60B	PEG	-	EPS next Q	-0.85	Inst Own	109.27%	Short Float	27.86%	Perf Quarter	1.48%
Income	-6.89M	P/S	10.18	EPS this Y	100.51%	Inst Trans	11.55%	Short Ratio	16.39	Perf Half Y	40.47%
Sales	184.42M	P/B	5.50	EPS next Y	-39671.58%	ROA	-2.00%	Short Interest	12.40M	Perf YTD	3.56%
Book/sh	5.98	P/C	6.58	EPS next 5Y	-22.85%	ROE	-2.37%	52W High	40.22 -18.27%	Perf Year	265.22%
Cash/sh	4.99	P/FCF	41.80	EPS past 3/5Y	64.49% 40.50%	ROIC	-1.95%	52W Low	5.35 514.39%	Perf 3Y	268.50%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	145.89% -	Gross Margin	97.73%	Volatility	7.29% 7.09%	Perf 5Y	-35.51%
Dividend TTM	-	EV/Sales	8.66	EPS Y/Y TTM	94.17%	Oper. Margin	-11.16%	ATR (14)	2.46	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	5.28	Sales Y/Y TTM	404.50%	Profit Margin	-3.73%	RSI (14)	44.62	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	5.28	EPS Q/Q	-439.83%	SMA20	-6.75%	Beta	1.21	Target Price	42.70
Payout	-	Debt/Eq	0.01	Sales Q/Q	-93.80%	SMA50	0.11%	Rel Volume	0.92	Prev Close	33.96
Employees	170	LT Debt/Eq	0.00	Earnings	Nov 04 AMC	SMA200	33.35%	Avg Volume	756.51K	Price	32.87
IPO	Jun 19, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	-14.40% 72.60%	Trades		Volume	693,587	Change	-3.21%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-24-26	Initiated	Wolfe Research	Outperform	$40
Feb-05-26	Initiated	Guggenheim	Buy	$60
Jan-05-26	Resumed	Chardan Capital Markets	Buy	$35
Jul-18-25	Initiated	Jefferies	Buy	$30
Dec-20-24	Initiated	Chardan Capital Markets	Buy	$24
Oct-14-24	Resumed	Leerink Partners	Outperform	$18
Mar-26-24	Upgrade	TD Cowen	Market Perform → Outperform
Nov-20-23	Resumed	JP Morgan	Neutral
Jul-25-23	Downgrade	TD Cowen	Outperform → Market Perform
May-01-23	Upgrade	BofA Securities	Underperform → Neutral	$9 → $12
Apr-26-23	Resumed	Canaccord Genuity	Buy	$24
Jan-06-23	Downgrade	BofA Securities	Buy → Underperform	$22 → $9
Oct-24-22	Upgrade	SVB Leerink	Mkt Perform → Outperform	$30
Jan-31-22	Initiated	Jefferies	Buy	$50
Dec-03-21	Initiated	BofA Securities	Buy	$43
Nov-22-21	Upgrade	JP Morgan	Neutral → Overweight	$41
May-18-21	Initiated	UBS	Neutral	$35
May-10-21	Upgrade	Wedbush	Neutral → Outperform
Apr-26-21	Resumed	Credit Suisse	Outperform	$58
Feb-10-21	Downgrade	Wedbush	Outperform → Neutral

Show Previous Ratings

Today 05:12PM	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
Mar-05-26 08:44AM	Dianthus Therapeutics, Inc. (DNTH) Stock Jumps 12.0%: Will It Continue to Soar? (Zacks)
Mar-04-26 05:06PM	The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome (Business Wire)
Feb-27-26 12:58PM	These Growth Stocks Form Classic Cup Bases. Here's Where To Buy. (Investor's Business Daily)
Feb-24-26 04:01PM	Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference (Business Wire)
12:59PM	Loading…
Feb-23-26 12:59PM	This Rare Disease Biotech Name Teases Around A Buy Point (Investor's Business Daily) +5.66%
Feb-18-26 04:01PM	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire) +10.94%
Feb-15-26 10:03AM	Stoke Therapeutics spotlights durable Dravet gains, Phase 3 timeline, and new ADOA program at summit (MarketBeat)
Feb-11-26 07:30AM	Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA) (Business Wire)
Feb-04-26 04:01PM	Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 (Business Wire) -5.30%
Jan-27-26 02:05PM	Anchor Line Partners Supports Stoke Therapeutics' Growth by Securing a 98,500 Square-Foot Lease in Waltham, MA (PR Newswire)
Jan-16-26 04:01PM	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
Jan-11-26 02:00PM	Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome (Business Wire)
Jan-06-26 04:01PM	Stoke Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference (Business Wire) +8.20%
Dec-16-25 04:01PM	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
01:16PM	Loading…
01:16PM	Biotech Leader Stoke Therapeutics Offers Multiple Entries As Revenue Surges 117% (Investor's Business Daily)
Dec-01-25 07:30AM	Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting (Business Wire)
Nov-28-25 10:07AM	Biotechs Are On A Big Run, And Two Stocks Have Buy Points (Investor's Business Daily)
Nov-18-25 04:01PM	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire) +7.31%
Nov-17-25 07:30AM	Stoke Therapeutics and Biogen Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments (Business Wire)
Nov-05-25 04:01PM	Stoke Therapeutics to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference (Business Wire) -9.94%
12:00PM	All You Need to Know About Stoke Therapeutics (STOK) Rating Upgrade to Buy (Zacks)
12:05AM	Stoke Therapeutics Inc (STOK) Q3 2025 Earnings Call Highlights: Strong Financial Position and ... (GuruFocus.com)
Nov-04-25 06:00PM	Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
04:01PM	Stoke Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates (Business Wire)
Oct-30-25 04:30PM	Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2025 Business and Financial Updates (Business Wire) -5.24%
Oct-20-25 07:30AM	Stoke Therapeutics Presents Two-Year Natural History Data from Patients with Autosomal Dominant Optic Atrophy (ADOA) (Business Wire)
Oct-19-25 03:09AM	H.C. Wainwright Maintains a Buy Rating on Stoke Therapeutics (STOK) (Insider Monkey)
Oct-16-25 04:30PM	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
Oct-10-25 10:06AM	Janux Therapeutics (JANX) Surges 6.8%: Is This an Indication of Further Gains? (Zacks)
04:30PM	Loading…
Oct-09-25 04:30PM	Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome (Business Wire)
09:25AM	Stoke Therapeutics (STOK) Surges 11.7%: Is This an Indication of Further Gains? (Zacks)
Oct-06-25 07:30AM	Stoke Therapeutics Appoints Ian F. Smith as Chief Executive Officer (Business Wire)
06:07AM	Gilead delays arrival of Biktarvy copycats; CDC updates vaccine schedule (BioPharma Dive)
Sep-16-25 04:30PM	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
Sep-05-25 04:16PM	ZoomInfo, International Money Express, and More Stocks See Action From Activist Investors (Barrons.com) +5.35% +6.33%
Sep-02-25 07:00AM	Stoke Therapeutics and Biogen Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome (Business Wire)
Aug-28-25 04:30PM	Stoke Therapeutics to Present at Upcoming Investor Conferences in September 2025 (Business Wire)
Aug-25-25 07:00AM	Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress (Business Wire)
Aug-18-25 04:30PM	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
Aug-13-25 03:12AM	Stoke Therapeutics Inc (STOK) Q2 2025 Earnings Call Highlights: Strong Growth and Strategic ... (GuruFocus.com) +24.98%
Aug-12-25 05:10PM	Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Stoke Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates (Business Wire)
06:38AM	First patient dosed in Phase III trial of zorevunersen for Dravet syndrome (Clinical Trials Arena)
Aug-11-25 09:26AM	Stoke Therapeutics Inc (STOK) Q2 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
07:00AM	Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome (Business Wire)
07:00AM	Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome (GlobeNewswire)
Aug-07-25 07:00AM	Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2025 Business and Financial Updates (Business Wire)
Aug-06-25 04:30PM	Stoke Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference (Business Wire)
Aug-05-25 06:35PM	Merus N.V. (MRUS) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
Jul-30-25 10:00AM	Analysts Estimate Stoke Therapeutics, Inc. (STOK) to Report a Decline in Earnings: What to Look Out for (Zacks)
Jul-18-25 10:17AM	Jefferies starts Stoke at Buy, sees $1 bln+ opportunity in rare epilepsy drug (Investing.com) +7.04%
Jul-16-25 04:30PM	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-10-25 07:00AM	Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress (Business Wire)
07:00AM	Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress (GlobeNewswire)
Jun-17-25 04:30PM	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-29-25 07:30AM	Stoke Therapeutics to Present at the Jefferies Global Healthcare Conference (Business Wire)
May-16-25 09:55AM	Wall Street Analysts Think Stoke Therapeutics (STOK) Could Surge 132.4%: Read This Before Placing a Bet (Zacks)
May-13-25 09:50AM	Stoke Therapeutics, Inc. (STOK) Tops Q1 Earnings and Revenue Estimates (Zacks) -7.56%
07:00AM	Stoke Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates (Business Wire)
May-12-25 06:33AM	Doximity Q4 Earnings Likely to Reflect Strong Product Momentum (Zacks)
May-01-25 12:44PM	BIIB's Q1 Earnings Miss, Revenues Top Mark, 2025 EPS Guidance Cut (Zacks)
10:01AM	CG Oncology, Inc. (CGON) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
09:28AM	Is Biogen At The 'Start Of A Turnaround' On Its Quarterly Beat? (Investor's Business Daily)
06:45AM	Biogen Easily Tops Earnings Forecasts As Leqembi, Skyclarys Sales Soar (Investor's Business Daily)
Apr-28-25 10:00AM	Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks)
Apr-24-25 06:53AM	Can Biogen Keep the Beat Streak Alive This Earnings Season? (Zacks)
Apr-22-25 12:00PM	Stoke Therapeutics (STOK) Upgraded to Buy: What Does It Mean for the Stock? (Zacks) +7.08%
04:00AM	Stoke Therapeutics (STOK) Soars 12.0%: Is Further Upside Left in the Stock? (Zacks)
Apr-01-25 04:30PM	Stoke Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference (Business Wire) -6.32% +5.94%
Mar-18-25 12:40PM	Stoke Therapeutics Stock Slips as CEO Steps Down (Investopedia)
12:40PM	Stoke Therapeutics Slips as CEO Steps Down (Investopedia)
08:05AM	Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
08:05AM	Stoke CEO exits; Medicare drug price talks advance (BioPharma Dive)
07:00AM	Stoke Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates (Business Wire)
06:58AM	Stoke Therapeutics Announces CEO Transition (Business Wire)
Mar-17-25 10:00AM	Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Feb-26-25 04:30PM	Stoke Therapeutics to Present at Upcoming Investor Conferences in March (Business Wire)
Feb-19-25 06:55AM	Biogen and Stoke Therapeutics to commercialise Dravet syndrome treatment (Pharmaceutical Technology)
Feb-18-25 01:32PM	Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal (Benzinga) -9.08%
08:00AM	Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments (Business Wire)
07:25AM	Biogen buys rights to Stokes rare epilepsy drug (BioPharma Dive)
Feb-05-25 08:51AM	Strength Seen in Stoke Therapeutics (STOK): Can Its 9.4% Jump Turn into More Strength? (Zacks)
Jan-08-25 04:30PM	Stoke Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
06:31AM	Tenvie raises $200M for brain drug R&D; Sana spikes on single patients results (BioPharma Dive)
Jan-07-25 07:00AM	Stoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome (Business Wire) -15.52%
Jan-06-25 04:30PM	Stoke Therapeutics to Host Webcast to Discuss Successful Global Regulatory Alignment for a Phase 3 Study of Zorevunersen as Potentially the First Disease Modifying Medicine for Dravet Syndrome (Business Wire)
Dec-06-24 12:00PM	Stoke Therapeutics Presents New Open-Label Extension (OLE) Study Data That Further Support the Potential for Zorevunersen as a Disease-Modifying Medicine for the Treatment of Dravet Syndrome (Business Wire) +5.57%
Dec-05-24 08:30AM	GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners (Business Wire)
Dec-04-24 07:00AM	Stoke Therapeutics Receives FDA Breakthrough Therapy Designation for Zorevunersen for the Treatment of Dravet Syndrome (Business Wire) +12.07%
Dec-02-24 08:00AM	Stoke Therapeutics Announces Plans to Present New Data that Support Zorevunersen as Potentially the First Disease-Modifying Medicine for Dravet Syndrome at the American Epilepsy Society 2024 Annual Meeting (Business Wire)
Nov-26-24 01:56AM	An RNA biotech draws the blueprint for a late-stage Dravet syndrome trial and beyond (Pharma Voice)
Nov-20-24 09:55AM	Stoke Therapeutics (STOK) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Nov-08-24 09:55AM	Wall Street Analysts Believe Stoke Therapeutics (STOK) Could Rally 66.84%: Here's is How to Trade (Zacks)
Nov-05-24 08:15AM	Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates (Business Wire)
Oct-29-24 10:01AM	Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-12-24 06:10PM	Stoke Therapeutics assumed with an Outperform at Leerink (TipRanks)
10:18AM	Stoke Therapeutics, Inc (STOK): Pioneering RNA Medicine for Genetic Diseases (Insider Monkey)
Sep-23-24 07:07PM	Skorpios Trust Reduces Stake in Stoke Therapeutics Inc (GuruFocus.com)

Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. It offers a wide range of relevant tissues including the central nervous system, eye, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hoitt Jason	Chief Patient Officer	Mar 15 '26	Option Exercise	0.00	10,000	0	13,988	Mar 17 05:26 PM
Leggett Thomas	Chief Financial Officer	Mar 15 '26	Option Exercise	0.00	14,750	0	14,750	Mar 17 05:26 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Mar 15 '26	Option Exercise	0.00	33,850	0	53,648	Mar 17 05:25 PM
Kaye Edward M. MD	Director	Mar 15 '26	Option Exercise	0.00	61,750	0	110,874	Mar 17 05:24 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Mar 15 '26	Option Exercise	0.00	25,475	0	37,731	Mar 17 05:23 PM
LEVIN ARTHUR A	Director	Mar 13 '26	Sale	36.80	605	22,264	4,237	Mar 17 05:23 PM
ARTHUR A LEVIN	Director	Mar 13 '26	Proposed Sale	36.48	605	22,070		Mar 13 04:19 PM
TZIANABOS ARTHUR	Interim Executive Chair	Mar 10 '26	Option Exercise	8.33	3,955	32,945	35,694	Mar 12 04:57 PM
TZIANABOS ARTHUR	Interim Executive Chair	Mar 10 '26	Sale	40.00	4,355	174,214	31,339	Mar 12 04:57 PM
Krainer Adrian R.	Director	Mar 10 '26	Sale	39.74	33,243	1,320,964	283,302	Mar 12 04:56 PM
ARTHUR TZIANABOS	Director	Mar 10 '26	Proposed Sale	38.31	90,508	3,467,361		Mar 10 04:39 PM
Krainer Adrian R.	Director	Mar 02 '26	Sale	39.66	7,229	286,715	316,545	Mar 04 04:28 PM
Adrian Krainer	Director	Mar 02 '26	Proposed Sale	36.41	40,472	1,473,586		Mar 02 04:42 PM
LEVIN ARTHUR A	Director	Dec 31 '25	Option Exercise	0.00	1,211	0	4,842	Jan 05 04:16 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Dec 08 '25	Sale	32.28	3,978	128,411	11,831	Dec 10 04:24 PM
Kaye Edward M. MD	Director	Dec 08 '25	Sale	32.27	13,430	433,385	49,124	Dec 10 04:23 PM
EDWARD M KAYE	Director	Dec 08 '25	Proposed Sale	30.87	13,430	414,584		Dec 08 04:40 PM
JONATHAN ALLAN	Officer	Dec 08 '25	Proposed Sale	30.87	3,978	122,801		Dec 08 04:38 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Dec 03 '25	Option Exercise	0.00	10,000	0	25,156	Dec 05 08:51 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Dec 05 '25	Sale	31.34	3,662	114,762	19,798	Dec 05 08:51 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Dec 04 '25	Sale	30.87	1,696	52,353	23,460	Dec 05 08:51 PM
Kaye Edward M. MD	Director	Dec 03 '25	Option Exercise	0.00	26,250	0	77,555	Dec 05 08:50 PM
Kaye Edward M. MD	Director	Dec 05 '25	Sale	31.32	8,548	267,761	62,554	Dec 05 08:50 PM
Kaye Edward M. MD	Director	Dec 04 '25	Sale	30.87	6,453	199,197	71,102	Dec 05 08:50 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Dec 03 '25	Option Exercise	0.00	6,000	0	25,612	Dec 05 08:49 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Dec 05 '25	Sale	31.29	8,785	274,898	15,809	Dec 05 08:49 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Dec 04 '25	Sale	30.87	1,018	31,425	24,594	Dec 05 08:49 PM
EDWARD M KAYE	Director	Dec 05 '25	Proposed Sale	31.05	2,181	67,720		Dec 05 04:38 PM
JONATHAN ALLAN	Officer	Dec 05 '25	Proposed Sale	31.05	7,781	241,600		Dec 05 04:29 PM
BARUCH TICHO	Officer	Dec 05 '25	Proposed Sale	31.05	1,989	61,758		Dec 05 04:29 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Dec 01 '25	Option Exercise	0.00	11,981	0	19,176	Dec 03 08:23 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Dec 03 '25	Sale	30.65	2,014	61,725	15,156	Dec 03 08:23 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Dec 02 '25	Sale	29.78	2,006	59,743	17,170	Dec 03 08:23 PM
Kaye Edward M. MD	Director	Dec 03 '25	Sale	30.65	1,070	32,793	51,305	Dec 03 08:22 PM
Kaye Edward M. MD	Director	Dec 02 '25	Sale	29.78	1,066	31,748	52,375	Dec 03 08:22 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Dec 01 '25	Option Exercise	0.00	12,357	0	24,188	Dec 03 08:20 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Dec 03 '25	Sale	30.65	2,292	70,245	19,612	Dec 03 08:20 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Dec 02 '25	Sale	29.78	2,284	68,023	21,904	Dec 03 08:20 PM
Krainer Adrian R.	Director	Nov 24 '25	Sale	29.72	40,472	1,202,719	323,774	Nov 26 04:06 PM
Adrian Krainer	Director	Nov 24 '25	Proposed Sale	29.34	40,472	1,187,448		Nov 24 04:24 PM
Krainer Adrian R.	Director	Nov 14 '25	Sale	26.98	40,472	1,092,058	364,246	Nov 18 04:22 PM
Adrian Krainer	Director	Nov 14 '25	Proposed Sale	26.07	40,472	1,055,105		Nov 14 04:29 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Nov 03 '25	Sale	25.72	5,931	152,566	7,195	Nov 05 04:20 PM
BARUCH TICHO	Officer	Nov 03 '25	Proposed Sale	30.04	5,931	178,167		Nov 03 04:22 PM
Kaye Edward M. MD	Director	Oct 08 '25	Option Exercise	0.60	25,000	15,000	74,124	Oct 10 04:12 PM
Kaye Edward M. MD	Director	Oct 08 '25	Sale	30.00	25,000	750,000	49,124	Oct 10 04:12 PM
EDWARD M KAYE	Director	Oct 08 '25	Proposed Sale	27.31	25,000	682,750		Oct 08 04:20 PM
Kaye Edward M. MD	Director	Oct 03 '25	Sale	25.09	42,461	1,065,206	49,124	Oct 07 04:26 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Oct 03 '25	Option Exercise	9.15	10,000	91,500	21,831	Oct 07 04:26 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Oct 03 '25	Sale	25.07	10,000	250,650	11,831	Oct 07 04:26 PM
EDWARD M KAYE	Director	Oct 03 '25	Proposed Sale	24.82	42,461	1,053,882		Oct 03 04:35 PM
JONATHAN ALLAN	Officer	Oct 03 '25	Proposed Sale	24.82	10,000	248,200		Oct 03 04:30 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Oct 01 '25	Sale	23.64	5,343	126,316	13,126	Oct 03 04:25 PM
LEVIN ARTHUR A	Director	Sep 30 '25	Option Exercise	0.00	1,211	0	3,631	Oct 01 04:47 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Sep 02 '25	Sale	19.87	5,501	109,325	18,469	Sep 03 05:53 PM
Kaye Edward M. MD	Director	Sep 03 '25	Sale	20.13	45,996	925,858	91,585	Sep 03 05:51 PM
Kaye Edward M. MD	Director	Sep 02 '25	Sale	20.14	14,860	299,260	137,581	Sep 03 05:51 PM
Kaye Edward M. MD	Director	Aug 29 '25	Sale	20.00	1,029	20,580	152,441	Sep 03 05:51 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Sep 02 '25	Option Exercise	7.07	9,150	64,690	33,098	Sep 03 05:50 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Aug 29 '25	Option Exercise	7.07	850	6,010	24,798	Sep 03 05:50 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Sep 02 '25	Sale	20.14	14,922	300,492	18,176	Sep 03 05:50 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Sep 03 '25	Sale	20.07	6,345	127,317	11,831	Sep 03 05:50 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Aug 29 '25	Sale	20.00	850	17,000	23,948	Sep 03 05:50 PM
BARUCH TICHO	Officer	Sep 02 '25	Proposed Sale	19.76	10,844	214,277		Sep 02 04:37 PM
EDWARD M KAYE	Director	Aug 29 '25	Proposed Sale	19.77	61,885	1,223,466		Aug 29 04:17 PM
JONATHAN ALLAN	Officer	Aug 29 '25	Proposed Sale	19.77	22,117	437,253		Aug 29 04:17 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Aug 18 '25	Sale	18.24	2,805	51,158	23,970	Aug 20 04:13 PM
Kaye Edward M. MD	Director	Aug 18 '25	Sale	18.24	12,126	221,154	153,470	Aug 20 04:12 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Aug 18 '25	Sale	18.24	1,683	30,695	23,948	Aug 20 04:11 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Aug 14 '25	Option Exercise	0.00	10,000	0	26,775	Aug 18 08:25 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Aug 14 '25	Option Exercise	0.00	6,000	0	25,631	Aug 18 08:24 PM
Kaye Edward M. MD	Director	Aug 14 '25	Option Exercise	0.00	26,250	0	165,596	Aug 18 08:23 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Aug 13 '25	Sale	15.00	13,712	205,680	19,631	Aug 15 04:31 PM
JONATHAN ALLAN	Officer	Aug 13 '25	Proposed Sale	13.53	13,712	185,523		Aug 13 04:29 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Aug 01 '25	Sale	12.82	4,504	57,724	16,775	Aug 05 04:05 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Jul 01 '25	Sale	11.63	4,503	52,379	21,279	Jul 02 04:09 PM
LEVIN ARTHUR A	Director	Jun 30 '25	Option Exercise	0.00	1,210	0	2,420	Jul 02 04:08 PM
BARUCH TICHO	Officer	Jul 01 '25	Proposed Sale	11.35	9,007	102,229		Jul 01 04:27 PM
Skorpios Trust	10% Owner	Jun 04 '25	Sale	10.20	3,000,000	30,600,000	3,906,181	Jun 06 04:20 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Jun 03 '25	Sale	10.03	6,471	64,892	25,782	Jun 04 08:30 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Jun 02 '25	Sale	10.00	1,745	17,450	32,253	Jun 04 08:30 PM
Ticho Barry	CHIEF MEDICAL OFFICER	May 02 '25	Sale	10.03	22,790	228,543	33,998	May 05 04:08 PM
Ticho Barry	CHIEF MEDICAL OFFICER	May 01 '25	Sale	10.00	3,841	38,410	56,788	May 05 04:08 PM
BARUCH S. TICHO	Officer	May 01 '25	Proposed Sale	9.76	34,847	340,107		May 01 04:45 PM
LEVIN ARTHUR A	Director	Mar 31 '25	Option Exercise	0.00	1,210	0	1,210	Apr 02 04:03 PM
Kaye Edward M. MD	Director	Mar 18 '25	Sale	8.67	10,382	90,012	148,253	Mar 20 06:15 PM
Kaye Edward M. MD	Director	Mar 19 '25	Sale	8.27	8,907	73,661	139,346	Mar 20 06:15 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Mar 18 '25	Sale	8.67	3,884	33,674	63,962	Mar 20 06:12 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Mar 19 '25	Sale	8.27	3,333	27,564	60,629	Mar 20 06:12 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Mar 18 '25	Sale	8.67	2,266	19,646	33,510	Mar 20 06:05 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Mar 19 '25	Sale	8.27	1,945	16,085	31,565	Mar 20 06:05 PM

Open in Screener

RNA

Atrium Therapeutics Inc

Mar 17 • 04:00PM ET

13.77

-0.02 -0.15 %

Healthcare • Biotechnology • USA • NASD

RNA Atrium Therapeutics Inc daily Stock Chart

Peers: MRNA VRTX SRPT ALNY IONS ARWR NBIX BLUE EXEL SGMO

| Held by: VB IWM XBI JSML VBR VTI VBK IWO SCHA VTWO

Index	-	P/E	-	EPS (ttm)	-	Insider Own	-	Shs Outstand	-	Perf Week	-6.13%
Market Cap	-	Forward P/E	-	EPS next Y	-	Insider Trans	-	Shs Float	-	Perf Month	-
Enterprise Value	-	PEG	-	EPS next Q	-	Inst Own	-	Short Float	-	Perf Quarter	-
Income	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	0.23	Perf Half Y	-
Sales	-	P/B	-	EPS next Y	-	ROA	-	Short Interest	0.43M	Perf YTD	-6.64%
Book/sh	-	P/C	-	EPS next 5Y	-	ROE	-	52W High	16.77 -17.89%	Perf Year	-
Cash/sh	-	P/FCF	-	EPS past 3/5Y	- -	ROIC	-	52W Low	13.06 5.44%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	4.52% -	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	1.14	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	-	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	-	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	-	EPS Q/Q	-	SMA20	-6.90%	Beta	-	Target Price	25.00
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	-6.90%	Rel Volume	0.16	Prev Close	13.79
Employees	-	LT Debt/Eq	-	Earnings	Nov 10 AMC	SMA200	-6.90%	Avg Volume	1.88M	Price	13.77
IPO	Jun 12, 2020	Option/Short	No / Yes	EPS/Sales Surpr.	-17.02% 545.33%	Trades		Volume	308,177	Change	-0.15%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-11-26	Initiated	Wells Fargo	Overweight	$25
Sep-17-25	Initiated	Roth Capital	Buy	$62
Jul-10-25	Resumed	Goldman	Buy	$55
Jun-24-25	Initiated	Bernstein	Outperform	$50
Jun-17-25	Initiated	Wolfe Research	Outperform	$55
Jun-11-25	Initiated	Raymond James	Strong Buy	$65
Mar-13-25	Initiated	Citigroup	Buy	$70
Mar-12-25	Initiated	BMO Capital Markets	Outperform	$72
Mar-07-25	Initiated	Scotiabank	Sector Outperform	$70
Dec-20-24	Initiated	H.C. Wainwright	Buy	$72
Nov-26-24	Initiated	RBC Capital Mkts	Outperform	$67
Sep-24-24	Initiated	Goldman	Buy	$59
Aug-28-24	Initiated	Barclays	Overweight	$63
May-03-24	Initiated	BofA Securities	Buy	$40
Mar-14-24	Initiated	Cantor Fitzgerald	Overweight	$60
May-22-23	Upgrade	Evercore ISI	In-line → Outperform	$20
Mar-31-23	Downgrade	Evercore ISI	Outperform → In-line	$20
Jul-20-22	Initiated	Chardan Capital Markets	Buy	$29
Jul-12-22	Initiated	Raymond James	Strong Buy	$29
Sep-07-21	Initiated	Evercore ISI	Outperform	$50

Show Previous Ratings

Today 08:09AM	Novartis Raises $11 Billion Bond to Fund $12 Billion Avidity Deal (GuruFocus.com)
Feb-27-26 04:05PM	Avidity (RNA) Moves Date for Shareholder Vote on Novartis Merger (Insider Monkey)
09:19AM	Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies (PR Newswire)
07:58AM	Atrium spins out of Avidity, aiming to target rare heart diseases with RNA (BioPharma Dive)
Feb-26-26 04:02PM	Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference (PR Newswire)
08:00AM	Loading…
Feb-23-26 08:00AM	Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders (PR Newswire)
Feb-18-26 05:00PM	The New England Journal of Medicine Publishes Results from Phase 1/2 MARINA Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1 (PR Newswire)
Feb-04-26 09:32AM	Novartis Beats on Q4 Earnings, Entresto Generics Pressure Sales (Zacks)
Feb-02-26 09:44PM	Avidity Biosciences Announces Expected Record Date for Spin-Off (PR Newswire)
Jan-22-26 07:10AM	Immunocore (IMCR) Soars 5.9%: Is Further Upside Left in the Stock? (Zacks)
Jan-13-26 11:43AM	JPM26: Novartis strengthens neuroscience portfolio with bolt-on deals (Pharmaceutical Technology)
Dec-09-25 08:57AM	Novartis Drops $1.7 Billion on AI Allergy Breakthrough (GuruFocus.com)
Dec-04-25 01:59PM	Avidity Biosciences, Inc. (RNA): A Bull Case Theory (Insider Monkey)
Dec-01-25 06:59PM	Halper Sadeh LLC Encourages RNA, TCBX, ATXS, FSUN Shareholders to Contact the Firm to Discuss Their Rights (PR Newswire)
Nov-25-25 02:00PM	FDA Greenlights Novartis' Gene Replacement Treatment for SMA (Zacks)
01:08PM	Loading…
01:08PM	Sarepta's Stock Rises on Positive Updates on DM1 Therapy (Zacks)
Nov-21-25 10:15AM	NVS Ups Sales Projections as Key Drugs and Collaborations Fuel Growth (Zacks)
Nov-20-25 03:45PM	These 15 stocks are still showing momentum - and a market-beating edge (MarketWatch)
09:31AM	US healthcare group Abbott bets on cancer screening technology in $23bn deal (Financial Times)
01:51AM	Novartis Expects Steady Sales Growth Through 2030 (The Wall Street Journal)
Nov-10-25 05:25PM	Avidity Biosciences, Inc. (RNA) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
04:05PM	Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights (PR Newswire)
Nov-07-25 04:34PM	Halper Sadeh LLC Encourages WTRG, PLYM, RNA Shareholders to Contact the Firm to Discuss Their Rights (PR Newswire)
Nov-04-25 10:00AM	Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
Nov-03-25 01:34AM	Avidity Biosciences (RNA) Soars 42% on $12-Billion Novartis Merger (Insider Monkey)
Oct-31-25 09:44AM	Here's Why Avidity Biosciences Stock Soared This Week (There's More to the Deal Than You Might Think) (Motley Fool)
Oct-30-25 12:23PM	Halper Sadeh LLC Encourages RNA, JAMF, AWK Shareholders to Contact the Firm to Discuss Their Rights (PR Newswire)
10:00AM	Analysts Estimate Avidity Biosciences, Inc. (RNA) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-29-25 02:49PM	Fresh List of Stocks With Short Squeeze Potential (Schaeffer's Research)
Oct-28-25 10:14AM	Novartis Lags Q3 Earnings, Announces $12B Avidity Biosciences Acquisition (Zacks)
09:42AM	Loading…
09:42AM	Warner Bros. Discovery upgraded, F5 downgraded: Wall Street's top analyst calls (The Fly)
09:17AM	Avidity Biosciences (RNA) Moves 42.4% Higher: Will This Strength Last? (Zacks)
06:26AM	Novartis Expects to Ride Out Patent Losses With Sales, Profit Growth Ahead (The Wall Street Journal)
06:11AM	S&P Futures Muted After Record Rally, FOMC Meeting and Earnings in Focus (Barchart)
05:24AM	Avidity Biosciences (RNA) Soars to All-Time High on Looming $12-Billion Merger with Novartis (Insider Monkey)
04:00AM	Novartis $12B Avidity deal shows a willingness to take big swings in neuroscience (Pharma Voice)
Oct-27-25 05:12PM	Why Avidity Biosciences Stock Blasted 42% Higher Today (Motley Fool)
05:09PM	Health Care Roundup: Market Talk (The Wall Street Journal)
04:54PM	This biotech's stock soared as investors look for the next buyout target (MarketWatch)
04:51PM	Stocks to Watch Monday: Amazon, Nvidia, Novartis, Keurig Dr Pepper (The Wall Street Journal)
04:34PM	These Stocks Are Moving the Most Today: Qualcomm, MP Materials, USA Rare Earth, Tesla, Avidity, Newmont, Microsoft, and More (Barrons.com)
01:01PM	HALPER SADEH LLC ENCOURAGES ADVM, PLYM, RNA SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS (PR Newswire)
12:55PM	Novartis Just Dropped $12 Billion on a Biotech Moonshot--Here's What Investors Need to Know (GuruFocus.com)
12:07PM	Why Avidity Biosciences And Dyne Therapeutics Stocks Soared 40% Monday (Investopedia)
11:16AM	Novartis Avidity Deal Is a Green Light for Biotech Rally (Barrons.com)
09:38AM	Stocks to Watch Monday: Nvidia, Novartis, Keurig Dr Pepper (The Wall Street Journal)
09:24AM	Novartis to buy Avidity for $12B, Keurig Dr Pepper raises outlook (Yahoo Finance Video)
08:25AM	5 Things to Know Before the Stock Market Opens (Investopedia)
08:19AM	USA Rare Earth, Iren, Novartis, Softbank: Trending Stocks (Yahoo Finance Video)
06:49AM	Fed, Tech Earnings and Trump-Xi Talks. Why One Matters Most for Markets. (Barrons.com)
06:08AM	MP Materials slumps, Avidity Biosciences surges and other movers (MarketWatch)
05:51AM	Novartis agrees to buy Avidity Biosciences for $12bn (Pharmaceutical Technology)
05:26AM	Dyne, Avidity stocks soar as Novartis strikes $12 bln biotech deal (Investing.com)
04:59AM	Stock Market Today: Dow set for 200-point rise, S&P 500 and Nasdaq to pop after weekend talks between U.S. and China (MarketWatch)
04:39AM	Jefferies sees Dyne as key beneficiary of Novartis Avidity buyout (Investing.com)
04:39AM	Novartis Deal Values Avidity Biosciences At $12 Billion (Barrons.com)
Oct-26-25 05:33PM	Novartis Agrees to Acquire Avidity Biosciences for $12 Billion (The Wall Street Journal)
04:25PM	Novartis acquiring US firm Avidity Biosciences for $12 bn (AFP)
03:43PM	Swiss drugmaker Novartis to buy Avidity Biosciences for $12 billion (USA TODAY)
03:29PM	Novartis Deal Values Avidity Biosciences At $12 Billion (Barrons.com)
01:07PM	Avidity Biosciences Enters into Agreement to be Acquired by Novartis AG (PR Newswire)
11:07AM	Novartis to acquire Avidity in $12B bet on RNA drugs for neuromuscular disease (BioPharma Dive)
Oct-16-25 09:00AM	Avidity Biosciences to Participate in Upcoming Investor Conference (PR Newswire)
Oct-13-25 09:00AM	Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026 (PR Newswire)
07:31AM	What Makes Avidity Biosciences (RNA) an Investment Choice? (Insider Monkey)
Oct-06-25 09:00AM	Avidity Biosciences to Present Data from EXPLORE44 Clinical Development Program of Del-Zota in DMD44 at 30th Annual Congress of the World Muscle Society (PR Newswire)
Sep-24-25 04:06AM	Avidity Biosciences (RNA) Announces Positive One-Year Data For its, Del-Zota (Insider Monkey)
Sep-17-25 09:33AM	Netflix upgraded, Five Below initiated: Wall Street's top analyst calls (The Fly)
Sep-15-25 04:01PM	Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire)
Sep-13-25 12:01PM	Avidity Biosciences (RNA) Gets 9% Boost from Higher PT, Rating (Insider Monkey)
Sep-12-25 06:45AM	Takeda poaches top Lilly exec; Maze soars on early PKU drug data (BioPharma Dive)
Sep-10-25 04:01PM	Avidity Biosciences Announces Proposed Public Offering of Common Stock (PR Newswire)
07:00AM	Avidity Biosciences' Del-zota Demonstrated Reversal of Disease Progression Across Key Functional Endpoints in EXPLORE44 and EXPLORE44-OLE Phase 1/2 Trial in People Living with DMD44 (PR Newswire)
12:59AM	Cantor Fitzgerald Reiterates a Buy Rating on Avidity Biosciences (RNA) (Insider Monkey)
Aug-27-25 09:00AM	Avidity Biosciences to Participate in Upcoming Investor Conferences (PR Newswire)
Aug-25-25 02:23PM	RNA Stock Moves More Than 30% in a Week: What's Driving This Rally? (Zacks)
Aug-14-25 09:15AM	Clene Inc. (CLNN) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
Aug-13-25 08:15AM	Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
Aug-12-25 05:15PM	Fate Therapeutics (FATE) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
Aug-07-25 05:10PM	Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights (PR Newswire)
10:19AM	Avidity (RNA) Gets 26% Jump on Potential Takeover (Insider Monkey)
Aug-06-25 05:10PM	Arcutis Biotherapeutics, Inc. (ARQT) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
12:47PM	Avidity Biosciences Rockets As Novartis Reportedly Mulls A Takeover Deal (Investor's Business Daily)
12:00PM	Avidity Biosciences stock soars on Novartis takeover approach report (Investing.com)
11:41AM	Novartis weighs deal for biotech Avidity Biosciences, FT reports (Reuters)
Jul-28-25 09:39AM	Facioscapulohumeral Muscular Dystrophy Pipeline Market Insight Report 2025 \| In-depth Analysis of 10+ Companies and 12+ Pipeline Drugs (GlobeNewswire)
09:00AM	Avidity Biosciences Announces Completion of Enrollment for HARBOR, the First Global Phase 3 Trial of Delpacibart Etedesiran (del-desiran) for Treatment of DM1 and Provides Guidance on Regulatory Submission (PR Newswire)
Jul-26-25 11:03AM	Avidity (RNA) Jumps 9.2% on Drug Candidate's Breakthrough Therapy Designation (Insider Monkey)
Jul-23-25 09:00AM	Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Zotadirsen (del-zota) for the Treatment of DMD in People with Mutations Amenable to Exon 44 Skipping (PR Newswire)
Jul-13-25 06:15AM	Raymond James Predicts Up to ~760% Surge for These 2 Strong Buy Stocks (TipRanks)
Jun-11-25 08:03PM	Avidity Biosciences, Inc. (RNA) Initiated with a Strong Buy at Raymond James (Insider Monkey)
09:45AM	Raymond James bullish on biotech firms on favorable valuation (Investing.com)
09:00AM	Avidity Biosciences to Present Topline Data from Phase 1/2 FORTITUDE Trial of Del-brax in People Living with Facioscapulohumeral Muscular Dystrophy at 32nd Annual FSHD Society International Research Congress (PR Newswire)
Jun-10-25 09:25AM	Avidity Biosciences price target raised to $75 from $65 at Chardan (TipRanks)
Jun-09-25 02:04PM	Avidity Biosciences Touts Encouraging Functional Gains And Biomarker Reductions In Rare Muscular Weakness Disease Trial (Benzinga)
07:01AM	Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Participants (PR Newswire)
07:00AM	Avidity Biosciences Announces the Accelerated Approval Regulatory Pathway in the U.S. is Open for Del-Brax and Initiates the Global, Confirmatory Phase 3 FORWARD Study in FSHD (PR Newswire)
May-21-25 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
May-08-25 05:55PM	Avidity Biosciences, Inc. (RNA) Reports Q1 Loss, Misses Revenue Estimates (Zacks)

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hughes Steven George	Chief Medical Officer	Jan 21 '26	Sale	72.45	4,895	354,643	31,599	Jan 23 05:34 PM
Boyce Sarah	President and CEO	Jan 21 '26	Sale	72.45	14,387	1,042,338	269,007	Jan 23 05:34 PM
Flanagan W. Michael	Chief Scientific Officer	Jan 21 '26	Sale	72.45	6,534	473,388	85,093	Jan 23 05:33 PM
MacLean Michael F	Chief Financial Officer	Jan 21 '26	Sale	72.45	4,542	329,068	59,290	Jan 23 05:33 PM
LEVIN ARTHUR A	Director	Jan 21 '26	Sale	72.45	1,758	127,367	16,562	Jan 23 05:33 PM
McCarthy Teresa	Chief Human Resources Officer	Jan 21 '26	Sale	72.45	2,929	212,206	113,938	Jan 23 05:33 PM
Boyce Sarah	President and CEO	Jan 07 '26	Sale	72.23	8,576	619,444	283,394	Jan 09 05:13 PM
Calderaro Charles III	Chief Technical Officer	Jan 07 '26	Sale	72.23	3,727	269,201	49,797	Jan 09 05:13 PM
McCarthy Teresa	Chief Human Resources Officer	Jan 07 '26	Sale	72.23	1,965	141,932	116,867	Jan 09 05:13 PM
Moriarty John B	Chief Legal Officer	Jan 07 '26	Sale	72.23	2,374	171,474	74,557	Jan 09 05:12 PM
MacLean Michael F	Chief Financial Officer	Jan 07 '26	Sale	72.23	1,974	142,582	63,832	Jan 09 05:12 PM
Hughes Steven George	Chief Medical Officer	Jan 07 '26	Sale	72.23	2,373	171,402	36,494	Jan 09 05:12 PM
Flanagan W. Michael	Chief Scientific Officer	Jan 07 '26	Sale	72.23	2,373	171,402	91,627	Jan 09 05:12 PM
Hughes Steven George	Chief Medical Officer	Oct 22 '25	Option Exercise	10.16	2,209	22,443	41,076	Oct 24 04:56 PM
Hughes Steven George	Chief Medical Officer	Oct 22 '25	Sale	47.54	2,209	105,015	38,867	Oct 24 04:56 PM
McCarthy Teresa	Chief Human Resources Officer	Oct 15 '25	Option Exercise	22.34	20,000	446,800	117,130	Oct 17 04:27 PM
McCarthy Teresa	Chief Human Resources Officer	Oct 15 '25	Sale	50.15	20,000	1,003,058	97,130	Oct 17 04:27 PM
Mosbrooker Eric	Chief Commercial Officer	Oct 03 '25	Option Exercise	9.05	6,562	59,386	61,562	Oct 07 04:11 PM
Mosbrooker Eric	Chief Commercial Officer	Oct 03 '25	Sale	45.38	6,562	297,771	55,000	Oct 07 04:11 PM
Hughes Steven George	Chief Medical Officer	Sep 22 '25	Option Exercise	10.16	2,208	22,433	41,075	Sep 23 04:57 PM
Hughes Steven George	Chief Medical Officer	Sep 22 '25	Sale	40.58	2,208	89,601	38,867	Sep 23 04:57 PM
McCarthy Teresa	Chief Human Resources Officer	Sep 15 '25	Option Exercise	22.34	15,000	335,100	112,130	Sep 17 04:03 PM
McCarthy Teresa	Chief Human Resources Officer	Sep 15 '25	Sale	41.41	15,000	621,142	97,130	Sep 17 04:03 PM
Hughes Steven George	Chief Medical Officer	Sep 15 '25	Option Exercise	6.57	1,542	10,131	40,409	Sep 17 04:02 PM
Hughes Steven George	Chief Medical Officer	Sep 15 '25	Sale	45.41	1,542	70,022	38,867	Sep 17 04:02 PM
Flanagan W. Michael	Chief Scientific Officer	Sep 11 '25	Option Exercise	14.22	20,000	284,400	100,195	Sep 12 04:07 PM
Flanagan W. Michael	Chief Scientific Officer	Sep 11 '25	Sale	38.94	20,000	778,702	80,195	Sep 12 04:07 PM
WILLIAM MICHAEL FLANAGAN	Officer	Sep 11 '25	Proposed Sale	46.40	20,000	928,000		Sep 11 04:24 PM
WILSON TROY EDWARD	Director	Sep 05 '25	Option Exercise	12.48	14,500	180,960	83,925	Sep 09 05:53 PM
WILSON TROY EDWARD	Director	Sep 05 '25	Sale	50.00	29,500	1,475,000	54,425	Sep 09 05:53 PM
Boyce Sarah	President and CEO	Sep 05 '25	Option Exercise	1.24	50,000	62,000	355,871	Sep 05 06:56 PM
Boyce Sarah	President and CEO	Sep 05 '25	Sale	49.95	50,000	2,497,435	305,871	Sep 05 06:56 PM
Mosbrooker Eric	Chief Commercial Officer	Sep 03 '25	Option Exercise	9.05	6,563	59,395	61,563	Sep 05 06:32 PM
Mosbrooker Eric	Chief Commercial Officer	Sep 03 '25	Sale	47.07	6,563	308,936	55,000	Sep 05 06:32 PM
SARAH BOYCE	Director	Sep 05 '25	Proposed Sale	48.47	50,000	2,423,500		Sep 05 04:25 PM
WILSON TROY EDWARD	Chairman	Sep 05 '25	Proposed Sale	50.00	95,052	4,752,600		Sep 05 04:10 PM
ERIC MOSBROOKER	Officer	Sep 03 '25	Proposed Sale	47.23	19,688	929,864		Sep 03 04:31 PM
Gallagher Kathleen P.	Chief Program Officer	Sep 02 '25	Sale	47.42	188	8,915	50,204	Sep 02 08:30 PM
Boyce Sarah	President and CEO	Aug 28 '25	Option Exercise	1.24	25,000	31,000	330,871	Aug 29 04:28 PM
Boyce Sarah	President and CEO	Aug 28 '25	Sale	49.39	25,000	1,234,700	305,871	Aug 29 04:28 PM
SARAH BOYCE	Director	Aug 28 '25	Proposed Sale	47.82	25,000	1,195,500		Aug 28 04:21 PM
Hughes Steven George	Chief Medical Officer	Aug 22 '25	Option Exercise	10.16	2,208	22,433	41,075	Aug 22 05:20 PM
Hughes Steven George	Chief Medical Officer	Aug 22 '25	Sale	46.40	2,208	102,462	38,867	Aug 22 05:20 PM
McCarthy Teresa	Chief Human Resources Officer	Aug 15 '25	Option Exercise	22.34	10,000	223,400	107,130	Aug 15 05:50 PM
McCarthy Teresa	Chief Human Resources Officer	Aug 15 '25	Sale	46.56	10,000	465,632	97,130	Aug 15 05:50 PM
TERESA MCCARTHY	Officer	Aug 15 '25	Proposed Sale	46.07	45,000	2,073,150		Aug 15 04:27 PM
MacLean Michael F	Chief Financial Officer	Aug 06 '25	Sale	42.73	30,914	1,320,844	65,806	Aug 15 04:09 PM
Hughes Steven George	Chief Medical Officer	Aug 13 '25	Option Exercise	6.57	1,542	10,131	40,409	Aug 15 04:07 PM
Hughes Steven George	Chief Medical Officer	Aug 13 '25	Sale	46.66	1,542	71,950	38,867	Aug 15 04:07 PM
STEVEN GEORGE HUGHES	Officer	Aug 13 '25	Proposed Sale	46.23	9,709	448,847		Aug 13 04:31 PM
Mosbrooker Eric	Chief Commercial Officer	Aug 06 '25	Option Exercise	9.05	124,687	1,128,417	185,807	Aug 08 05:45 PM
Mosbrooker Eric	Chief Commercial Officer	Aug 06 '25	Sale	44.06	130,807	5,763,697	55,000	Aug 08 05:45 PM
WILSON TROY EDWARD	Director	Aug 06 '25	Option Exercise	12.14	29,500	358,260	91,425	Aug 08 05:42 PM
WILSON TROY EDWARD	Director	Aug 06 '25	Sale	45.00	65,554	2,949,930	17,776	Aug 08 05:42 PM
WILSON TROY EDWARD	Director	Aug 06 '25	Sale	45.00	29,500	1,327,500	69,425	Aug 08 05:42 PM
LEVIN ARTHUR A	Director	Aug 06 '25	Option Exercise	22.34	107,500	2,401,550	127,150	Aug 08 05:41 PM
LEVIN ARTHUR A	Director	Aug 06 '25	Sale	47.62	107,500	5,118,881	19,650	Aug 08 05:41 PM
Hughes Steven George	Chief Medical Officer	Aug 06 '25	Option Exercise	12.21	47,451	579,180	90,517	Aug 08 05:39 PM
Hughes Steven George	Chief Medical Officer	Aug 06 '25	Sale	42.74	81,434	3,480,269	38,867	Aug 08 05:39 PM
ERIC MOSBROOKER	Officer	Aug 06 '25	Proposed Sale	38.26	130,807	5,004,676		Aug 06 04:23 PM
STEVEN GEORGE HUGHES	Officer	Aug 06 '25	Proposed Sale	38.26	81,434	3,115,665		Aug 06 04:23 PM
ARTHUR LEVIN	Director	Aug 06 '25	Proposed Sale	38.26	107,500	4,112,950		Aug 06 04:23 PM
MICHAEL MACLEAN	Officer	Aug 06 '25	Proposed Sale	38.26	30,914	1,182,770		Aug 06 04:22 PM
WILSON TROY EDWARD	Chairman	Aug 06 '25	Proposed Sale	45.00	95,054	4,277,430		Aug 06 04:08 PM
Moriarty John B	Chief Legal Officer	Aug 04 '25	Sale	36.21	2,245	81,291	47,755	Aug 05 05:27 PM
Gallagher Kathleen P.	Chief Program Officer	Jun 17 '25	Sale	30.24	911	27,549	50,392	Jun 18 06:02 PM
KATHLEEN GALLAGHER	Officer	Jun 17 '25	Proposed Sale	29.80	911	27,148		Jun 17 04:19 PM
Flanagan W. Michael	Chief Scientific Officer	Jun 11 '25	Option Exercise	14.22	20,000	284,400	100,195	Jun 12 06:18 PM
Flanagan W. Michael	Chief Scientific Officer	Jun 11 '25	Sale	32.88	20,000	657,694	80,195	Jun 12 06:18 PM
WILLIAM MICHAEL FLANAGAN	Officer	Jun 11 '25	Proposed Sale	33.62	20,000	672,400		Jun 11 04:31 PM
Gallagher Kathleen P.	Chief Program Officer	Jun 02 '25	Option Exercise	16.65	5,875	97,819	56,429	Jun 04 04:48 PM
Gallagher Kathleen P.	Chief Program Officer	Jun 02 '25	Sale	32.48	5,875	190,833	50,554	Jun 04 04:48 PM
KATHLEEN GALLAGHER	Officer	Jun 02 '25	Proposed Sale	30.98	5,875	182,008		Jun 02 04:37 PM
Gallagher Kathleen P.	Chief Program Officer	May 01 '25	Option Exercise	16.65	5,875	97,819	56,429	May 02 07:55 PM
Gallagher Kathleen P.	Chief Program Officer	May 01 '25	Sale	32.40	5,875	190,324	50,554	May 02 07:55 PM
KATHLEEN GALLAGHER	Officer	May 01 '25	Proposed Sale	32.65	5,875	191,819		May 01 04:57 PM
Gallagher Kathleen P.	Chief Program Officer	Apr 01 '25	Option Exercise	14.81	5,875	87,004	56,100	Apr 03 04:56 PM
Gallagher Kathleen P.	Chief Program Officer	Apr 01 '25	Sale	27.83	5,875	163,486	50,554	Apr 03 04:56 PM
Hughes Steven George	Chief Medical Officer	Mar 20 '25	Sale	31.06	9,578	297,491	72,850	Mar 21 06:44 PM
Boyce Sarah	President and CEO	Mar 20 '25	Sale	31.06	31,540	979,563	305,871	Mar 21 06:42 PM
Flanagan W. Michael	Chief Scientific Officer	Mar 20 '25	Sale	31.06	11,780	365,868	80,195	Mar 21 06:40 PM
MacLean Michael F	Chief Financial Officer	Mar 20 '25	Sale	31.06	7,935	246,425	96,720	Mar 21 06:38 PM
McCarthy Teresa	Chief Human Resources Officer	Mar 20 '25	Sale	31.06	7,778	241,583	97,130	Mar 21 06:36 PM

STOK

Stoke Therapeutics Inc

RNA

Atrium Therapeutics Inc

Upgrade your FINVIZ experience